Related Experiment Video

Updated: Jun 3, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Sorafenib in renal cell carcinoma

José Ángel Arranz1, Miguel Ángel Climent, José Luis González-Larriba

  • 1Jefe de la Sección de Tumores Genitourinarios, Hospital General Universitario Gregorio Marañón, Madrid, Spain. jarranza.oncomed@gmail.com

Critical Reviews in Oncology/Hematology
|March 23, 2011
PubMed

Insights

Molecular-targeted therapies like sorafenib show promise for metastatic renal cell carcinoma (RCC) resistant to chemotherapy. These multikinase inhibitors offer a new treatment avenue, inhibiting tumor growth and blood vessel formation.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Metastatic renal cell carcinoma (RCC) exhibits resistance to traditional chemotherapy.
  • Molecular-targeted therapies, specifically multikinase inhibitors, are now recommended for RCC treatment.
  • These inhibitors target tumor cell proliferation and angiogenesis.

Purpose of the Study:

  • To evaluate the safety and efficacy of sorafenib in metastatic RCC.
  • To explore sorafenib's utility in special patient populations and across different treatment lines.

Main Methods:

  • Review of expanded-access studies and non-randomized trials.
  • Analysis of sorafenib's performance in elderly patients, those with renal failure, cerebral metastases, and treatment-naïve patients.
  • Assessment of sorafenib's role in first-line and second-line settings, including monotherapy and combination strategies.

Main Results:

  • Sorafenib demonstrated safety and efficacy in metastatic RCC, including special populations.
  • No cross-resistance was observed when sorafenib was used as a second-line treatment after other targeted therapies.
  • Expanded-access studies confirmed sorafenib's tolerability and effectiveness.

Conclusions:

  • Sorafenib is a well-tolerated tyrosine kinase inhibitor effective in metastatic RCC.
  • Its efficacy extends to special populations and shows potential in various treatment sequences.
  • Ongoing trials will further define sorafenib's optimal role in RCC management.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...